Lobular Breast Cancer
Tuesday, December 5 • 3:25 p.m. – 5:15 p.m. • Stars at Night Ballroom 1-2

Presentation: Biological peculiarities of ILC

Christine Desmedt, PhD
Laboratory for Translational Breast Cancer Research/KU Leuven,
Leuven, Belgium

What is your presentation about?
Approximately 15% of patients with breast cancer have invasive lobular breast cancer (ILC). ILC differs in many ways from the most common breast cancer subtype, called non-special type (NST). In my presentation, I will review the biological differences between ILC and NST, both at the primary and metastatic level, and highlight their relevance.

What makes this topic important in 2023?
While many patients with breast cancer have ILC, this is a subtype which is less documented and still under-investigated.